Epilepsy Drugs Market

Executive Summary

Epilepsy Drugs Market was valued at US $6,766.73 million in 2021 and is projected to grow at 1.84% CAGR over the forecast period to reach US $7,547.46 million by 2027. Epilepsy Drugs Market represented US $241.86 million opportunity over 2019-2021 and estimated to create US $780.72 million opportunity in 2027 over 2021.

Epilepsy Drugs from Consainsights analyses the Epilepsy Drugs Market in the Life Sciences industry over the forecast period to 2027.

Epilepsy Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Epilepsy Drugs segmentation includes Drugs, Distribution Channel and Geography.

Based on the Drugs, the Epilepsy Drugs analysis covers First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics.

In Drugs segment, First Generation Anti-epileptics segment has highest cagr growth of 1.63%.

Based on the Distribution Channel, the Epilepsy Drugs analysis covers Hospital Pharmacy, Pharmacy Stores, Others.

In Distribution Channel segment, Hospital Pharmacy segment has highest cagr growth of 1.63%.

Based on the region, the Epilepsy Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A., and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Drugs

Introduction

In 2021, First Generation Anti-epileptics segment has the highest revenue of US $4,185.99 million and is expected to grow at CAGR of 1.63% by 2027 First Generation Anti-epileptics segment has highest cagr growth of 1.63%.

First Generation Anti-epileptics

First Generation Anti-epileptics segment was valued at US $4,036.37 million in 2019 and is projected to grow at 1.63% CAGR over the forecast period to reach US $4,668.96 million by 2027. First Generation Anti-epileptics segment represented US $149.62 million opportunity over 2019-2021 and estimated to create US $482.97 million opportunity in 2027 over 2021.

Second Generation Anti-epileptics

Second Generation Anti-epileptics segment was valued at US $2,432.36 million in 2019 and is projected to grow at 1.63% CAGR over the forecast period to reach US $2,813.56 million by 2027. Second Generation Anti-epileptics segment represented US $90.16 million opportunity over 2019-2021 and estimated to create US $291.04 million opportunity in 2027 over 2021.

Third Generation Anti-epileptics

Third Generation Anti-epileptics segment was valued at US $56.14 million in 2019 and is projected to grow at 1.63% CAGR over the forecast period to reach US $64.94 million by 2027. Third Generation Anti-epileptics segment represented US $2.08 million opportunity over 2019-2021 and estimated to create US $6.72 million opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Hospital Pharmacy segment has the highest revenue of US $4,214.47 million and is expected to grow at CAGR of 1.63% by 2027 Hospital Pharmacy segment has highest cagr growth of 1.63%.

Hospital Pharmacy

Hospital Pharmacy segment was valued at US $4,063.83 million in 2019 and is projected to grow at 1.63% CAGR over the forecast period to reach US $4,700.73 million by 2027. Hospital Pharmacy segment represented US $150.64 million opportunity over 2019-2021 and estimated to create US $486.25 million opportunity in 2027 over 2021.

Pharmacy Stores

Pharmacy Stores segment was valued at US $1,202.94 million in 2019 and is projected to grow at 1.63% CAGR over the forecast period to reach US $1,391.46 million by 2027. Pharmacy Stores segment represented US $44.59 million opportunity over 2019-2021 and estimated to create US $143.94 million opportunity in 2027 over 2021.

Others

Others segment was valued at US $1,258.10 million in 2019 and is projected to grow at 1.63% CAGR over the forecast period to reach US $1,455.27 million by 2027. Others segment represented US $46.64 million opportunity over 2019-2021 and estimated to create US $150.54 million opportunity in 2027 over 2021.